menu
The endocannabinoid system targeted therapeutics market is projected to be over USD 5 billion by 2030
The endocannabinoid system targeted therapeutics market is projected to be over USD 5 billion by 2030
The endocannabinoid system targeted therapeutics market is projected to be over USD 5 billion by 2030

The endocannabinoid system targeted therapeutics market is projected to be over USD 5 billion by 2030

So far, more than 100different cannabinoids have been identified, and there is a growing body ofevidence supporting the clinical benefits of this class of compounds intreating the symptoms of a wide variety of chronic health conditions

 

Roots Analysis is pleased toannounce the publication of its recent study, titled, “Endocannabinoid System Targeted Therapeutics Market,2020-2030.“

 

The report features an extensive study of thecurrent market landscape, offering an informed opinion on the likely adoptionof endocannabinoid system targeting drugs, over the next decade. The reportfeatures an in-depth analysis, highlighting the diverse capabilities ofstakeholders engaged in this domain. In addition to other elements, the studyincludes:

§ Adetailed assessment of the current market landscape of drugdevelopers engaged in the development of endocannabinoid system targeted therapeutics.

§ Detailed profiles ofdevelopers of endocannabinoidsystem targeted therapeutics (shortlisted onthe basis of the number of development programs).

§ An in-depth analysis ofnearly 600 grants that have been awarded to research institutes engaged in endocannabinoidsystem targeted therapeutics projects.

§ An analysis of thepartnerships that have been established in this domain, in the recent past.

§ A detailed analysis ofthe various mergers and acquisitions that have taken place in this domain, between 2016-2020

§ An insightful chessboardanalysis highlighting the most popular drug development strategies / pathsadopted by various drug developers in the domain of endocannabinoidsystem targeted therapeutics.

§ A detailed marketforecast, featuring analysis of the current and projected future opportunityacross key market segments (listed below)

§ Target Disease Indication

§ Cancer

§ Genetic Disorders

§ Neurological Indications

§ Others

  • Route of Administration

§ Oral

§ Inhalation

  • Key Geographies

§ North America

§ Europe

§ Asia-Pacific and the Restof the World

 

Keycompanies covered in the report

§  GW Pharmaceuticals

§  Corbus Pharmaceuticals

§  Tilray

§  Tetra Bio-Pharma

§  Botanix Pharmaceuticals

§  Kalytera Therapeutics

§  Therapix Biosciences

§  Echo Pharmaceuticals

§  Avicanna

§  GB Sciences

 

Formore information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html

 

Other Recent Offerings 

1.     Neoantigen TargetedTherapies Market, 2019-2030

2.     Blood-Brain Barrier(BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug DeliveryTechnology Platforms and Therapeutics

3.    Bispecific AntibodyTherapeutics Market (4th Edition), 2019-2030

4.     ContinuousManufacturing Market (Small Molecules and Biologics), 2020 – 2030

 

Contact:
Gaurav Chaudhary
+1 (415) 800 3415

+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies,sharing fresh and independent perspectives in the bio-pharmaceutical industry.The in-depth research, analysis and insights are driven by an experiencedleadership team which has gained many years of significant experience in thissector. If you’d like help with your growing business needs, get in touch atinfo@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com